ATE229073T1 - Protein e25a, methoden zu dessen herstellung und anwendung - Google Patents

Protein e25a, methoden zu dessen herstellung und anwendung

Info

Publication number
ATE229073T1
ATE229073T1 AT97939804T AT97939804T ATE229073T1 AT E229073 T1 ATE229073 T1 AT E229073T1 AT 97939804 T AT97939804 T AT 97939804T AT 97939804 T AT97939804 T AT 97939804T AT E229073 T1 ATE229073 T1 AT E229073T1
Authority
AT
Austria
Prior art keywords
protein
cancer
nucleic acid
refractory prostate
hormone refractory
Prior art date
Application number
AT97939804T
Other languages
English (en)
Inventor
Robert E Reiter
Owen N Witte
Charles L Sawyers
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE229073T1 publication Critical patent/ATE229073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97939804T 1996-09-06 1997-09-05 Protein e25a, methoden zu dessen herstellung und anwendung ATE229073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2556996P 1996-09-06 1996-09-06
PCT/US1997/015606 WO1998010069A2 (en) 1996-09-06 1997-09-05 E25a PROTEIN, METHODS FOR PRODUCTION AND USE THEREOF

Publications (1)

Publication Number Publication Date
ATE229073T1 true ATE229073T1 (de) 2002-12-15

Family

ID=21826823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939804T ATE229073T1 (de) 1996-09-06 1997-09-05 Protein e25a, methoden zu dessen herstellung und anwendung

Country Status (7)

Country Link
US (2) US6093800A (de)
EP (1) EP0942972B1 (de)
AT (1) ATE229073T1 (de)
AU (1) AU4181897A (de)
CA (1) CA2265889A1 (de)
DE (1) DE69717664D1 (de)
WO (1) WO1998010069A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1980617A1 (de) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU775272B2 (en) 1999-10-28 2004-07-29 Agensys, Inc. 36P6D5: secreted tumor antigen
WO2002043575A2 (en) * 2000-12-01 2002-06-06 Duke University Zinc alpha-2-glycoprotein as indicator of cancer
WO2002057417A2 (en) * 2000-12-15 2002-07-25 Origene Technologies, Inc. Angiogenesis gene and modulators
DK1573022T3 (da) * 2001-04-10 2011-09-12 Agensys Inc Nukleinsyre og tilsvarende protein betegnet 184P1E2, der er egnede til behandling og påvisning af cancer
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (de) * 2001-08-31 2006-04-26 Chiron Corp Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP1546714A4 (de) * 2002-08-30 2007-12-05 Univ Texas Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
WO2008137500A2 (en) * 2007-05-01 2008-11-13 The Brigham And Women's Hospital Immunosuppression with antibody against itm2a
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP3711768A1 (de) 2013-04-18 2020-09-23 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR102748354B1 (ko) 2016-06-01 2024-12-31 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757695A3 (de) * 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostata-spezifisches Membranantigen

Also Published As

Publication number Publication date
US7030232B1 (en) 2006-04-18
US6093800A (en) 2000-07-25
DE69717664D1 (de) 2003-01-16
WO1998010069A2 (en) 1998-03-12
EP0942972A2 (de) 1999-09-22
WO1998010069A3 (en) 1998-05-07
CA2265889A1 (en) 1998-03-12
EP0942972B1 (de) 2002-12-04
AU4181897A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE396266T1 (de) Trp8 krebsmarker
CY1105212T1 (el) Αντισωματα αντι-april και κυτταρα υβριδωματος
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
WO2004092338A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
DE69933989D1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
ATE301676T1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
AU9021898A (en) Prostate tumor polynucleotide and antigen compositions
ATE478952T1 (de) 36p6d5: ausgeschiedenes tumorprotein
ATE350662T1 (de) Markerproteine für prostatakrebs
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
EP1377596A4 (de) Ttk in der diagnose und als therapeutisches target bei krebs
DE69126038D1 (de) Diagnose von krebs-metastasen durch das mts-1 gen
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
BR0312483A (pt) Anticorpos e seus usos
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
EP1243653A3 (de) E25a Protein, Methoden zur Herstellung und Verwendung
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties